Solid Bioscience SEC Filings

Form 4 filed for Ilan Ganot (director) reports option and restricted stock unit grants on 08/14/2025. The reporting person received an employee stock option to buy 37,500 shares at an exercise price of $6.17, exercisable through 08/14/2035. In addition, 18,750 restricted stock units (RSUs) were granted, each representing the contingent right to one share. Both holdings are reported as indirectly beneficially owned (I) via wife. The RSUs and option vest over four years, with 50% vesting on the second anniversary of the August 14, 2025 grant date and 25% each year thereafter. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Ganot on 08/18/2025.

Solid Biosciences Inc. reported that its Chief Operating Officer, David T. Howton, was granted equity awards on 08/14/2025 consisting of an employee stock option to buy 150,000 shares at an exercise price of $6.17 per share with an expiration date of 08/14/2035, and 75,000 restricted stock units (RSUs) that each convert into one share. After these grants, Mr. Howton beneficially owns 150,000 option shares and 75,000 RSUs, all held directly. The RSUs and the option vest over four years: 50% vests on the second anniversary of the grant and 25% vests on each of the third and fourth anniversaries.

Kevin Tan, CFO & Treasurer of Solid Biosciences Inc. (SLDB), received equity awards on August 14, 2025. The Form 4 shows a grant of 125,000 employee stock options with an exercise price of $6.17 and 62,500 restricted stock units (RSUs), each RSU representing a right to one share. The awards vest over four years: 50% of the original shares vest on the second anniversary of the grant and 25% vest annually thereafter until the fourth anniversary. Following the reported transaction, Mr. Tan beneficially owns 125,000 shares from the option and 62,500 shares from RSUs as direct ownership. The Form 4 was signed by Kimberly Cornwell as attorney-in-fact on 08/18/2025.

Paul Herzich, Chief Technology Officer of Solid Biosciences Inc. (SLDB), reported equity awards granted on 08/14/2025. The filing shows an employee stock option for 100,000 underlying shares with a stated exercise price of $6.17 and an associated record showing 100,000 shares of common stock underlying that option. The filing also reports 50,000 restricted stock units (RSUs), each representing a contingent right to one share, for 50,000 shares of common stock. The RSUs and the option were granted on the same date and the RSUs vest over four years: 50% on the second anniversary of the grant and 25% annually thereafter until the fourth anniversary. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Herzich on 08/18/2025.

Solid Biosciences Inc. (SLDB) reported an equity award to Chief Medical Officer Gabriel Brooks comprised of an employee stock option to purchase 142,500 shares at an exercise price of $6.17 and 71,250 restricted stock units (RSUs), both granted on 08/14/2025. The option expires on 08/14/2035 and both awards are held directly by the reporting person. The RSUs convert on a one-for-one basis to common stock. The awards vest over four years: 50% of the original shares vest on the second anniversary of the grant and 25% of the original shares vest each year thereafter until the fourth anniversary. The Form 4 was signed by an attorney-in-fact on 08/18/2025.

Jessie Hanrahan, identified as a Director and the company's Chief Regulatory Officer, acquired equity in Solid Biosciences Inc. (SLDB) on 08/14/2025. The filing reports an employee stock option to purchase 142,500 shares at a $6.17 exercise price and 71,250 restricted stock units (RSUs), each RSU representing a right to one share. Following the transactions Hanrahan beneficially owns 142,500 options and 71,250 RSUs. The awards were granted on the stated date and include vesting terms: 50% of the original RSU grant vests on the second anniversary of the grant date and 25% annually thereafter until the fourth anniversary. The form is signed by an attorney-in-fact on 08/18/2025.

Solid Biosciences (SLDB) reported an equity award to its President and CEO, Alexander Cumbo. On 08/14/2025 Mr. Cumbo was granted an employee stock option to buy 337,500 shares at an exercise price of $6.17 expiring 08/14/2035, and 168,750 restricted stock units (RSUs) each representing one share. Following the grants, he beneficially owns 337,500 option shares and 168,750 RSUs, all held directly. The RSUs and the option were granted the same date and vest over four years: 50% of the original number vests on the second anniversary and 25% of the original number vests on each of the third and fourth anniversaries. The Form 4 was signed on 08/18/2025 by an attorney-in-fact for Mr. Cumbo.

RA Capital and affiliated persons report owning 7,997,510 shares of Solid Biosciences (SLDB), representing approximately 9.9% of the outstanding common stock. The reported position includes 5,673,193 shares directly held by RA Capital Healthcare Fund, L.P., additional small direct holdings through related accounts and pre-funded warrants exercisable for up to 3,722,085 shares subject to a beneficial ownership blocker that prevents exercise above 9.99% ownership. Recent open-market purchases disclosed include 529,768 shares at a weighted-average of $4.49 and smaller buys at prices between $3.80 and $4.50 per share. RA Capital, Peter Kolchinsky and Rajeev Shah disclose shared voting and dispositive power over the reported shares and state delegations of voting/dispositive authority from certain funds.

Solid Biosciences Inc. Schedule 13G/A filing by Commodore Capital entities

Commodore Capital LP and Commodore Capital Master LP filed an amendment to Schedule 13G reporting zero shares beneficially owned of Solid Biosciences Inc. (CUSIP 83422E204), representing 0.0% of the class. The filing lists the issuers' principal office at 500 Rutherford Avenue, Charlestown, Massachusetts, and gives filing addresses for the two filers in New York and the Cayman Islands. Both filers state no sole or shared voting or dispositive power over any shares and certify the securities were not acquired to influence control of the issuer. The filing is signed by Michael Kramarz for both entities and references a Joint Filing Agreement as an exhibit.